Allarity Therapeutics has announced a Phase 2 clinical trial to evaluate the combination of stenoparib, a dual PARP/Wnt pathway inhibitor, with temozolomide for patients with recurrent Small Cell Lung ...
Adjuvant temozolomide post-radiotherapy significantly improves survival in 1p/19q non-co-deleted anaplastic astrocytomas, especially in IDH-mutated cases, reducing mortality risk by 35%. Concurrent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results